+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 1Year - 18Years
All Genders
ID05717712

Phase 1 Study of Ad-TD-nsIL12 Virus Injection for Treating Primary Pediatric Diffuse Intrinsic Pontine Glioma

Led by Capital Medical University · Updated on 2024-02-28

18

Participants Needed

1

Research Sites

156 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, tolerability, and toxicity of a new oncolytic virus called Ad-TD-nsIL12, given by injection into tumors, for children aged 1 to 18 years with newly diagnosed diffuse intrinsic pontine glioma DIPG. This early phase 1 clinical trial uses a dose escalation design to observe how patients respond to the virus treatment according to standard safety criteria NCI-CTCAE V5.0. Participants will receive multiple intratumoral injections of Ad-TD-nsIL12 after undergoing a stereotactic biopsy and placement of an Ommaya reservoir through the biopsy channel. Two injections are given shortly after surgery, spaced 3 days apart, followed by additional injections every 3 weeks plus or minus 4 days. The virus doses vary based on patient cohorts, ranging from 3x109 to 3x1010 viral particles suspended in 1 ml saline. During the trial, patients will be monitored closely with safety assessments at 3 months after the virus injection. Researchers will also evaluate tumor response at 3 months, overall survival at 12 months, and quality of life over 2 years. Sample collections will occur at 3 months to support these evaluations. This study is led by Capital Medical University and runs until 2028, focusing on careful observation of patients throughout the course of treatment and follow-up.

CONDITIONS

Brief Title

Oncolytic Virus Ad-TD-nsIL12 for Primary Pediatric Diffuse Intrinsic Pontine Glioma

Research Team

X

Xiao Qian, Dr.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here